New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
04:55 EDTJPM, JPM, JPM, PJC, PJC, PJC, JNJ, JNJ, JNJ, COV, COV, COV, EW, EW, EW, MDT, MDT, MDTElsevier Business Intelligence to hold a conference
IN3 Medical Device 360 is being held in Dublin, Ireland on April 8-10.
News For JPM;PJC;JNJ;COV;EW;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 20, 2015
07:30 EDTJNJAchillion downgraded on valuation at JMP Securities
Subscribe for More Information
07:16 EDTMDTLeerink to hold a booth tour at EuroPCR
Subscribe for More Information
06:17 EDTJNJAchillion downgraded to Neutral from Buy at UBS
Subscribe for More Information
05:30 EDTEWEdwards Lifesciences announces outcomes for patients treated with SAPIEN 3 valve
Edwards Lifesciences announced that 30-day outcomes for intermediate-risk patients treated transfemorally with the SAPIEN 3 transcatheter aortic valve at centers in Europe and Canada demonstrated very low mortality and stroke rates, and no severe paravalvular leaks. These independently adjudicated data are consistent with the outcomes recently reported in a similar study of 1,000 patients treated at 51 centers in the United States. In the multi-center study of 101 intermediate-risk patients, all-cause mortality was 1 percent. The frequency of other important complications was also low: the disabling stroke rate was 2 percent, major vascular complications were 2 percent and the permanent pacemaker rate was 4 percent. The investigators also noted that the SAPIEN 3 valve had excellent hemodynamic performance, with very low incidence of significant paravalvular regurgitation, as only 2.3 percent of patients had moderate paravalvular leaks and there were no reports of severe leaks.
May 19, 2015
16:10 EDTJNJAchillion enters into collaboration for HCV with Janssen
Achillion (ACHN) announced that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of Achillion's lead hepatitis C virus, or HCV, assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Additionally, in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation JJDC, Inc. will invest $225M in Achillion and, in return, receive approximately 18.4M newly issued, unregistered shares of Achillion at a price of $12.25 per share. The transactions, including the equity sale, are subject to customary closing conditions, including termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act. Transitional clinical development and technology transfer activities under the collaboration are expected to take place over the next several months.
15:42 EDTJPMBanks' settlement over forex rigging to be announced tomorrow, CNBC says
Several banks are said to plan to plead guilty and pay "billions" in fines in a settlement over their roles in foreign exchange manipulation that is expected to be announced Wednesday, according to CNBC's Kate Kelly. Prior media reports have listed Barclays (BCS), Royal Bank of Scotland (RBS), UBS (UBS), JPMorgan (JPM) and Citigroup (C) as having been in talks with U.K. and U.S. authorities for their roles in foreign currency rigging.
09:37 EDTJPMActive equity options trading on open
Subscribe for More Information
09:21 EDTEWEdwards Lifesciences voluntarily pauses enrollment for Fortis clinical program
Subscribe for More Information
08:48 EDTEWEdwards Lifesciences reports positive results from treatment with SAPIEN 3
Subscribe for More Information
08:40 EDTMDTMedtronic sees FY15 revenue $20.3B, may not compare to consensus $28.15B
Subscribe for More Information
08:40 EDTMDTMedtronic sees Q4 adjusted EPS at upper half of $1.08-1.13, consensus $1.10
Subscribe for More Information
May 18, 2015
09:46 EDTJPMMPLX enters common unit sales agreement for up to $500M
Subscribe for More Information
09:27 EDTMDTMedtronic announces study results showing CRT system optimizes treatment
Subscribe for More Information
07:12 EDTJPMBarclays expected to face over GBP250M in fines for rigging, Telegraph says
Subscribe for More Information
May 15, 2015
13:33 EDTMDTMedtronic: TYRX antibacterial envelope reduces cardiac device infection rates
Subscribe for More Information
10:47 EDTJPMNCR Corp. working with JPMorgan on sale, dealReporter says
Subscribe for More Information
08:12 EDTMDTMedtronic Micra TPS meets initial safety, performance measures
Subscribe for More Information
07:50 EDTJPMDOJ tearing up prior UBS rigging settlement after new violations, WSJ reports
Subscribe for More Information
07:35 EDTJNJMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
06:18 EDTJPMJPMorgan reports April Net Credit Losses 2.34% vs. 2.61% last month
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use